New CSO key to driving disruptive technologies development :

Dr Daniel Turner has been appointed as Chief Scientific Officer by Enhanc3D Genomics, developers of disruptive technologies aimed at unlocking the 3D spatial genome for target and biomarker discovery. Click to read more...

Related Keywords

Manchester , United Kingdom , Wellcome Sanger , Hazel Jones , Daniel Turner , Dan Turner , University Of Manchester Institute Science , Technology Development , Wellcome Trust Sanger Institute , Weill Cornell Medical College , University Of Oxford , Chief Scientific Officer , Chief Operating Officer , Oxford Nanopore Technologies , Senior Vice President , Vice President , Senior Director , Sequencing Technology Development , Weill Cornell Medical , Manchester Institute , Chief Executive Officer , Development , Genomics , Technology , Chief , Officer , Senior , Burner , Cientific , Nhancd , Technologies ,